Pretzel Therapeutics Inc. has launched with a $72.5 million series A financing to pioneer novel therapies to modulate mitochondrial function to treat rare genetic diseases and common diseases of aging.
Autobahn Therapeutics Inc. has closed a US$32.7 million financing to support the company's continued work in the treatment of central nervous system (CNS) disorders and the advancement of ABX-002 through phase I and into phase II proof-of-concept studies for treatment-resistant depression (TRD).
Kuria Therapeutics Inc. has closed its first fundraising round to support ongoing preclinical development activities ahead of a planned series A raise.
Photys Therapeutics Inc. raised a $75 million series A financing to develop phosphorylation-inducing chimeric small-molecule medicines to fix dysfunctional proteins. Photys, of Cambridge, Mass., was founded by the Longwood Fund and Amit Choudhary of Brigham and Women’s Hospital and the Broad Institute of MIT and Harvard University.
Shanghai Junshi Biosciences Co. Ltd. plans to raise up to ¥3.969 billion (US$570 million) by issuing no more than 70 million A shares to target subscribers on the Shanghai STAR Market.
RSS
